Feeds:
Posts
Comments

Posts Tagged ‘Herceptin debate’

WALL STREET JOURNAL: Dendreon Corp expects to file for marketing approval for advanced prostate cancer immunotherapy treatment Provenge in mid-November and hopes to get final FDA approval in the middle of next year. READ MORE>

NEW PROSTATE CANCER INFOLINK: It is worth remembering that Provenge is not a “drug” in any normal sense of the term. READ MORE>

Provenge is strictly a form of individual cell-based immunotherapy in which cells from the patient’s own body are extracted, modified, and then re-infused back into the patient.

Every single dose of Provenge therefore has to be individually created.

PROSTABLOG NZ: The pressure on NZ’s drug approval organisation, Pharmac, to fast-track Provenge to Kiwi patients is shaping to be another Herceptin debate.

In that case, it seems only a very loud and effective campaign by sufferers succeeded in getting the expensive breast cancer treatment past Pharmac’s drug subsidisation process.

If Provenge has to be individually manufactured for each patient, you can bet the doses will cost thousands of dollars.

Pharmac may be spared the dilemma beyond next year, since it seems the manufacturer will not be able to fulfill the demand in the US, let alone other countries.

Read Full Post »